Long-term survival and late relapses in acute leukaemia in adults
| Autor: | B. E. Christensen, Hans Brincker |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Adult
Pediatrics medicine.medical_specialty Time Factors Adolescent Population Recurrence hemic and lymphatic diseases Acute lymphocytic leukemia Antineoplastic Combined Chemotherapy Protocols Long term survival Humans Medicine education education.field_of_study Adult patients business.industry Intensive treatment Remission Induction Age Factors Hematology Middle Aged Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease Leukemia Myeloid Acute Leukemia Lymphoblastic leukaemia business Acute myeloblastic leukaemia |
| Zdroj: | British Journal of Haematology. 74:156-160 |
| ISSN: | 1365-2141 0007-1048 |
| DOI: | 10.1111/j.1365-2141.1990.tb02559.x |
| Popis: | Summary 34 out of 403 apparently unselected adult patients with acute leukaemia referred to a single department from 1970 through 1989 survived more than 3 years. The cumulative rate of relapse after 3 years was 39% in patients with acute myeloblastic leukaemia (AML) and 74% in patients with acute lymphoblastic leukaemia (ALL). The latest relapse was observed 75 months after diagnosis in AML and 98 months after diagnosis in ALL. 65% of the long-term survivors were able to undertake normal physical activity, 26% had decreased activity, and 9% were unable to work. 5-year survival for all patients, whether treated or not, during two successive decades was 16% versus 18% and 5% versus 6%, respectively, for ALL and AML. The departmental results were identical with population-based national results. Only in patients 15–49 years of age with AML was there evidence that more intensive treatment had led to better survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text